GUIDANCE DOCUMENT
Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations Draft Guidance for Industry and Food and Drug Administration Staff January 2025
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- FDA-2024-D-4488
- Issued by:
-
Guidance Issuing OfficeCenter for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research
This draft guidance document provides recommendations regarding the contents of marketing submissions for devices that include artificial intelligence (AI)-enabled device software functions including documentation and information that will support FDA’s evaluation of safety and effectiveness. The recommendations reflect a comprehensive approach to the management of risk throughout the device total product life cycle (TPLC). To support the development of appropriate documentation for FDA’s assessment of the device, this draft guidance also proposes recommendations for the design, development, and implementation of AI-enabled devices that manufacturers may wish to consider using throughout the TPLC.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2024-D-4488.